| Primary |
| Hiv Infection |
36.2% |
| Drug Use For Unknown Indication |
27.2% |
| Antiretroviral Therapy |
7.7% |
| Drug Exposure During Pregnancy |
7.7% |
| Prophylaxis Against Hiv Infection |
6.0% |
| Acquired Immunodeficiency Syndrome |
2.6% |
| Compression Fracture |
1.7% |
| Osteoporosis |
1.7% |
| Prophylaxis |
1.7% |
| Bronchospasm |
1.3% |
| Systemic Antiviral Treatment |
1.3% |
| Cardiac Disorder |
0.9% |
| Coronary Artery Disease |
0.9% |
| Human Immunodeficiency Virus Transmission |
0.9% |
| Angina Pectoris |
0.4% |
| Chemotherapy |
0.4% |
| Congenital Hiv Infection |
0.4% |
| Cytomegalovirus Infection |
0.4% |
| Diarrhoea |
0.4% |
| Fungal Infection |
0.4% |
|
| Nephropathy Toxic |
10.3% |
| Premature Baby |
10.3% |
| Protein Urine Present |
7.7% |
| Skin Striae |
7.7% |
| Drug Exposure During Pregnancy |
5.1% |
| Gastric Ulcer |
5.1% |
| Hypokalaemia |
5.1% |
| Immune Reconstitution Syndrome |
5.1% |
| Meningitis Cryptococcal |
5.1% |
| Overdose |
5.1% |
| Pneumocystis Jiroveci Infection |
5.1% |
| Pulmonary Embolism |
5.1% |
| Pulmonary Hypertension |
5.1% |
| Adrenal Insufficiency |
2.6% |
| Arrhythmia |
2.6% |
| Blood Triglycerides Increased |
2.6% |
| Cytomegalovirus Colitis |
2.6% |
| Drug Level Decreased |
2.6% |
| Drug Toxicity |
2.6% |
| Electrocardiogram Qt Prolonged |
2.6% |
|
| Secondary |
| Hiv Infection |
76.5% |
| Prophylaxis Against Hiv Infection |
4.7% |
| Antiretroviral Therapy |
3.8% |
| Antiviral Prophylaxis |
2.5% |
| Drug Exposure During Pregnancy |
2.1% |
| Product Used For Unknown Indication |
1.7% |
| Drug Use For Unknown Indication |
1.3% |
| Hiv Test Positive |
1.2% |
| Acquired Immunodeficiency Syndrome |
0.9% |
| Tuberculosis |
0.8% |
| Prophylaxis |
0.7% |
| Human Immunodeficiency Virus Transmission |
0.6% |
| Maternal Exposure Timing Unspecified |
0.5% |
| Cytomegalovirus Chorioretinitis |
0.5% |
| Mycobacterium Avium Complex Infection |
0.5% |
| Bipolar Disorder |
0.4% |
| Hypertension |
0.4% |
| Osteoporosis |
0.4% |
| Sepsis Neonatal |
0.4% |
| Asthma |
0.3% |
|
| Progressive External Ophthalmoplegia |
11.7% |
| Drug Exposure During Pregnancy |
10.3% |
| Premature Baby |
9.7% |
| Sepsis |
7.6% |
| Premature Rupture Of Membranes |
6.9% |
| Osteonecrosis |
6.2% |
| Thrombocytopenia |
4.8% |
| Vomiting |
4.8% |
| Sinus Tachycardia |
4.1% |
| Drug Interaction |
3.4% |
| Maternal Drugs Affecting Foetus |
3.4% |
| Meningitis Cryptococcal |
3.4% |
| Pneumonia |
3.4% |
| Pregnancy |
3.4% |
| Cryptorchism |
2.8% |
| Hyperlipidaemia |
2.8% |
| Maternal Exposure During Pregnancy |
2.8% |
| Medulloblastoma |
2.8% |
| Myocardial Infarction |
2.8% |
| Renal Failure Acute |
2.8% |
|
| Concomitant |
| Hiv Infection |
63.4% |
| Pneumocystis Jiroveci Pneumonia |
7.0% |
| Pulmonary Tuberculosis |
3.2% |
| Antiretroviral Therapy |
2.7% |
| Febrile Bone Marrow Aplasia |
2.3% |
| Interstitial Lung Disease |
2.3% |
| Mycobacterial Infection |
2.0% |
| Cytomegalovirus Oesophagitis |
1.9% |
| Antifungal Prophylaxis |
1.8% |
| Bipolar Disorder |
1.5% |
| Maternal Exposure During Pregnancy |
1.5% |
| Hiv Test Positive |
1.4% |
| Diabetes Mellitus |
1.3% |
| Hepatitis C |
1.3% |
| Polyneuropathy |
1.3% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
1.2% |
| Pregnancy |
1.2% |
| Prophylaxis |
1.0% |
| Postoperative Wound Infection |
0.9% |
| Viral Infection |
0.8% |
|
| Renal Failure Acute |
10.1% |
| Drug Exposure During Pregnancy |
9.0% |
| Ultrasound Antenatal Screen Abnormal |
9.0% |
| Pulmonary Embolism |
7.9% |
| Thrombocytopenia |
7.9% |
| Pregnancy |
6.7% |
| Leukocytoclastic Vasculitis |
4.5% |
| Premature Baby |
4.5% |
| Adverse Event |
3.4% |
| Diarrhoea |
3.4% |
| Nephropathy Toxic |
3.4% |
| Pseudomembranous Colitis |
3.4% |
| Pyrexia |
3.4% |
| Rash |
3.4% |
| Renal Dysplasia |
3.4% |
| Stevens-johnson Syndrome |
3.4% |
| Subcutaneous Abscess |
3.4% |
| Tetany |
3.4% |
| Therapeutic Response Unexpected |
3.4% |
| Ventricular Septal Defect |
3.4% |
|
| Interacting |
| Antiretroviral Therapy |
53.8% |
| Hiv Infection |
25.6% |
| Acne |
10.3% |
| Drug Use For Unknown Indication |
5.1% |
| Back Pain |
2.6% |
| International Normalised Ratio |
2.6% |
|
| Drug Interaction |
28.6% |
| Hypertriglyceridaemia |
28.6% |
| International Normalised Ratio Decreased |
28.6% |
| Viral Load Increased |
14.3% |
|
